Brought to you by 
Dynogen licenses Phase II GI compound from Mitsubishi
29 Nov 2004
Executive Summary
Dynogen Pharmaceuticals (in-licenses neuroscience-based compounds to apply to genitourinoary and gastrointestinal indications) has acquired exclusive rights in most of the world to develop Mitsubishi Pharma's pumosetrag, which showed good safety and pharmacokinetic profiles in Phase II.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Dynogen licenses Phase II GI compound from Mitsubishi
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice